Drug Profile
Zirconium silicate - ZS Pharma
Alternative Names: LOKELMA; Lokelma; Sodium zirconium cyclosilicate; UXSi-9; Ziconite; Zircon; ZS; ZS 9Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator ZS Pharma
- Developer AstraZeneca; ZS Pharma
- Class Heavy metals; Minerals; Silicates; Transition elements
- Mechanism of Action Potassium binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperkalaemia
- Phase III Kidney disorders
Most Recent Events
- 01 Dec 2023 Discontinued - Phase-III for Hyperkalaemia (Adjunctive treatment) in USA, Argentina, Brazil, Bulgaria, Canada, China, India, Japan, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand, Turkey, Ukraine, Vietnam (PO) (NCT05056727) (AstraZeneca pipeline, February 2024)
- 01 Dec 2023 AstraZeneca terminates a phase III DIALIZE-Outcomes trial for Hyperkalaemia (In adults, In elderly) in Argentina, Austria, Brazil, Bulgaria, Canada, China, Czech Republic, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, Peru, Poland, Russia, Slovakia, Spain, Thailand, Turkey, Ukraine, United Kingdom, Vietnam, USA and Taiwan (PO, Suspension) (NCT04847232)
- 17 Nov 2022 AstraZeneca terminates the phase III NEUTRALIZE trial in Hyperkalaemia and Metabolic acidosis associated with Chronic kidney disease (PO) due to a higher than expected screen fail rate (NCT04727528)